- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Health Canada Approval of RYBREVANT® (amivantamab), the First and Only Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Targeting both cancer-driving and resistance mechanism pathways, RYBREVANT® offers a unique treatment approach for an underserved patient population
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
An analysis showed benefit of XARELTO® plus aspirin in reducing thrombotic hospitalizations for PAD patients with and without chronic kidney disease (CKD) A separate analysis demonstrated PAD patients who received XARELTO® plus aspirin in addition to statin therapy had the lowest risk of the composite of major adverse cardiovascular events (MACE) or major adverse limb events (MALE) compared to all other treatment groups in the study
New Janssen Initiative Aims to Advance Equitable Care and Address Hidden Threat of Amputation Related to Peripheral Artery Disease (PAD)
Through Save Legs. Change Lives.™, Janssen seeks to elevate PAD research, collaboration, education and screening for communities placed at increased risk of cardiovascular disease
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
CABENUVA offers virologically suppressed adolescents 12 years of age or older living with HIV-1 an injectable treatment option with as few as six dosing days per year
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Adults living with HIV now have an option to start injectable regimen without the need for an oral lead-in period first
Janssen Initiates First-of-its-Kind Clinical Study to Bridge Critical Gaps in Care for People of Color with Moderate to Severe Plaque Psoriasis
The only large-scale prospective study in dermatology designed to generate key disease insights among Black, Hispanic, Asian, Indigenous and other people of color Study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities
South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides
The dapivirine ring is the first long-acting HIV prevention option designed specifically for women Women bear a disproportionate burden of the global HIV epidemic, especially in sub-Saharan Africa International Partnership for Microbicides developed the dapivirine ring through an exclusive license from the Janssen Pharmaceutical Companies of Johnson & Johnson
Janssen Seeks Approval of a New Indication for IMBRUVICA® (ibrutinib) for Use in Patients with Untreated Mantle Cell Lymphoma
Application based on Phase 3 SHINE study results, which investigated the safety and efficacy of all-oral ibrutinib in combination with bendamustine and rituximab in adult patients with previously untreated mantle cell lymphoma[1]
Johnson & Johnson Announces Landmark Agreement to Enable its COVID-19 Vaccine to be Manufactured and Made Available by an African Company for People Living in Africa
Aspen will manufacture and provide the Johnson & Johnson COVID-19 vaccine under its own brand name per the terms of agreement Ensuring equitable, global access to COVID-19 vaccines has been a pillar of Johnson & Johnson’s response since the earliest days of the pandemic The production of COVID-19 vaccines on multiple continents is critical to supporting an equitable response, controlling the pandemic, and improving long-term health security